Treatable renal failure found in non-ambulatory Duchenne muscular dystrophy patients

Neuromuscular Disorders

Volumn 25, Issue 10, 2015, Pages 754-757

  Motoki, Takahiro ^a   Shimizu Motohashi, Yuko ^a   Komaki, Hirofumi ^a   Mori Yoshimura, Madoka ^a   Oya, Yasushi ^a   Takeshita, Eri ^a   Ishiyama, Akihiko ^a   Saito, Takashi ^a   Nakagawa, Eiji ^a   Sugai, Kenji ^a   Murata, Miho ^a   Sasaki, Masayuki ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Chronic renal hypoperfusion; Cystatin C; Duchenne muscular dystrophy; Non ambulatory; Renal failure

Indexed keywords

CARVEDILOL; CYSTATIN C; ENALAPRIL; ERYTHROPOIETIN; FUROSEMIDE; HEMOGLOBIN; MERTIATIDE TC 99M; METOPROLOL; NITROGEN; SPIRONOLACTONE; TORASEMIDE; UREA; DYSTROPHIN;

ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ANURIA; ARTICLE; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DUCHENNE MUSCULAR DYSTROPHY; FATIGUE; FLUID INTAKE; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPOVOLEMIA; IMMOBILITY; KIDNEY FAILURE; KIDNEY SCINTISCANNING; LOSS OF APPETITE; MALE; MUSCLE WEAKNESS; NONINVASIVE VENTILATION; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL; UREMIA; WEIGHT REDUCTION; YOUNG ADULT; ADOLESCENT; BLOOD; COMPLICATION; DRINKING; GENETICS; MUTATION; RENAL INSUFFICIENCY; RISK FACTOR;

ADOLESCENT; ADULT; BLOOD UREA NITROGEN; CYSTATIN C; DRINKING; DYSTROPHIN; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 84941732305     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2015.07.006     Document Type: Article

References (19)

1. Bradley D., Parsons E. Newborn screening for Duchenne muscular dystrophy. Semin Neonatol 1998, 3:27-34.
2. Hoffman E.P., Brown R.H., Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51:919-928.
3. Eagle M., Bourke J., Bullock R., et al. Managing Duchenne muscular dystrophy: the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 2007, 27:470-475.
4. Viollet L., Thrush P.T., Flanigan K.M., Mendell J.R., Allen A.D. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol 2012, 110:98-102.
5. Eagle M., Baudouin S.V., Chandler C., Giddings D.R., Bullock R., Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002, 12:926-929.
6. Imai E. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease. Jpn J Nephrol 2012, 54:1031-1191. in Japanese.
7. Wang Z.M., Gallagher D., Nelson M.E., Matthews D.E., Heymsfield S.B. Total body skeletal muscle mass: evaluation of 24-h urinary creatinine excretion by computerized axial tomography. Am J Clin Nutr 1996, 63:863-869.
8. Viollet L., Gailey S., Thornton D.J., et al. Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve 2009, 40:438-442.
9. Inker L.A., Schmid C.H., Tighiouart H., et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012, 367:20-29.
10. Braat E., Hoste L., De Waele L., et al. Renal function in children and adolescents with Duchenne muscular dystrophy. Neuromuscul Disord 2015, 25:381-387.
11. Cimerman N., Brquljan P.M., Krasovec M., Suslovic S., Kos J. Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta 2000, 300:83-95.
12. Kazama J.J., Kutsuwada K., Ataka K., Maruyama H., Geiyo F. Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases. Nephron 2002, 91:13-20.
13. Matsumura T., Saito T., Fujimura H., Sakoda S. Renal dysfunction is a frequent complication in patients with advanced stage of Duchenne muscular dystrophy. Clin Neurol 2012, 52:211-217. in Japanese.
14. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010, 9:177-189.
15. Silverberg D.S., Wexler D., Iaina A., Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 2006, 26:296-306.
16. Kimura H., Hiramitsu S., Miyagishima K., et al. Cardio-renal interaction: impact of renal function and anemia on the outcome of chronic heart failure. Heart Vessels 2010, 25:306-312.
17. Loh N.Y., Newey S.E., Davies K.E., Blake D.J. Assembly of multiple dystrobrevin-containing complexes in the kidney. J Cell Sci 2000, 113:2715-2724.
18. Haenggi T., Schaub M.C., Fritschy J.M. Molecular heterogeneity of the dystrophin-associated protein complex in the mouse kidney nephron: differential alterations in the absence of utrophin and dystrophin. Cell Tissue Res 2005, 319:299-313.
19. Shimizu-Motohashi Y., Asakura A. Angiogenesis as a novel therapeutic strategy for Duchenne muscular dystrophy through decreased ischemia and increased satellite cells. Front Physiol 2014, 5:50.